<DOC>
	<DOCNO>NCT01876810</DOCNO>
	<brief_summary>The purpose study investigate effect gemfibrozil nicotine reinforcement cue-elicited craving . Other objective study include screen ability gemfibrozil aid smoking abstinence brief quit attempt examine validity use laboratory measure tobacco dependence predict smoking abstinence . It hypothesize gemfibrozil result diminish nicotine reinforcement , attenuate response smoking cue , increase smoking abstinence compare placebo . It also hypothesize laboratory measure prove valid predicting abstinence .</brief_summary>
	<brief_title>Initial Screening Gemfibrozil Novel Treatment Tobacco Addiction</brief_title>
	<detailed_description>Animal study show drug act agonist alpha-type peroxisome proliferator-activated receptor ( PPARα ) suppress nicotine self-administration , attenuate relapse nicotine-seeking behavior reinstatement model , block nicotine-induced neuronal firing dopamine release reward pathways brain . These result demonstrate synthetic PPARα agonist fibrate drug ( clofibrate , fenofibrate ) , use clinically treat elevate cholesterol triglyceride level . Thus , PPARα potential target treatment tobacco addiction . This first human study investigate whether fibrate drug ( gemfibrozil , Lopid® ) reduce nicotine reward aid smoker become tobacco abstinent . The objective study : 1. investigate effect gemfibrozil laboratory measure nicotine reinforcement cue-elicited crave 2. screen ability gemfibrozil aid smoking abstinence brief quit attempt 3. examine validity use laboratory measure tobacco dependence predict smoke abstinence possible gemfibrozil-related increase smoke abstinence This outpatient study conduct Center Addiction Mental Health ( CAMH ) Toronto , Canada . This site enroll 40 adult smoker intend quit smoke next 3 month . The study double-blind , placebo-controlled , crossover design compare effect gemfibrozil placebo . The study comprise two 2-week medication phase washout period least one week . At end first medication week laboratory measure take second medication week participant make quit attempt abstinence assess . Outcome measure include laboratory assessment nicotine reinforcement smoking cue reactivity . The measure nicotine reinforcement percentage nicotine cigarette puff choose forced-choice task . Measures cue reactivity include tobacco craving , mood , autonomic responsivity . Other measure day smoke abstinence quit-attempt week . Abstinence assess self-reports smoke breath carbon monoxide &lt; 5 ppm clinic visit . Other assessment abstinence include self-reported tobacco crave withdrawal .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>1965 year old male females smoke least 10 cigarette per day least 2 year intend quit smoking within next 3 month medically psychologically healthy determine screen criterion currently attempt quit smoking treatment tobacco addiction past 3 month use nicotine replacement product , bupropion , varenicline past 3 month aid quit reduce smoking use oral tobacco product past 3 month history drug alcohol dependence within last 5 year consumption 15 alcoholic drink per week average past month use illicit drug per week average past month current use gemfibrozil fibrate medication current use medication contraindicate gemfibrozil would interfere protocol opinion MAI/QI . This include , limited , anticoagulant , statin , fibrates , lipidlowering agent niacin herbal remedy , oral injected medication diabetes . preexist gallbladder disease operation past 12 month history current cardiovascular , liver , hepatic renal disease diabetes pregnant , nursing , become pregnant study use psychoactive drug medication reveal urine toxicology</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Gemfibrozil</keyword>
	<keyword>Nicotine Dependence</keyword>
	<keyword>Smoking</keyword>
	<keyword>Cigarettes</keyword>
</DOC>